地诺前列酮促胎膜早破孕妇宫颈成熟的临床研究

Clinical research on dinoprostone promoting uterine neck mature of pregnant women with premature rupture of membranes

目的:评价欣普贝生(地诺前列酮)对胎膜早破足月孕妇引产的有效性和安全性。方法:选取计划分娩的单胎初产妇200例,随机分为实验组(欣普贝生治疗组)100例和对照组(缩宫素治疗组)100例。比较两组宫颈Bishop评分、用药效果、新生儿结局及不良反应。结果:实验组与对照组用药前后宫颈Bishop评分差值分别为(6.59±1.68)分与(4.92±1.71)分,差异有统计学意义(t=6.963,P<0.001);实验组阴道分娩率(87.00%)高于对照组(71.00%)(χ2=7.715,P=0.005);两组总产程、羊水浑浊率差异均有统计学意义(P<0.05);而两组出血量比较差异无统计学意义(P=0.169)。欣普贝生和缩宫素临床使用均无严重不良反应。结论:欣普贝生(地诺前列酮)是一种有效的促宫颈成熟和引产药物,使用方便、安全可靠、适用于胎膜早破足月引产。

Objective： To evaluate of the effectiveness and safety of Showtime propess （dinoprostone） on premature rupture of membranes. Methods： 200 primipara planned delivery singleton were selected and randomly divided into the experimental （100 cases, Showtime propess treatment group） and control groups （100 cases, oxytocin treatment group） . Cervical Bishop score, medication effects, neonatal outcome and adverse reaction were detected. Results： Cervical Bishop score difference of experimental and control groups before and after treatment was 6. 59 ＋ 1.68 and 4. 92 _＋ 1.71 respectively, the difference was statistically significant （ t =6. 963, P 〈0. 001 ）. Vagi- nal delivery rate of experimental group （87.00%） was higher than that of control group （71.00% ）, the difference was statistically signifi- cant （X2 =7. 715, P = 0. 005）. There were significant differences in total labor and amniotic fluid turbidity （P 〈0. 05） , and there was no significant difference in bleeding volume between the two groups （P = 0. 169） . There were no serious adverse reaction in application of Showtime propess and oxytoein. Conclusion： Showtime propess （dinoprostone） is an effective drug for cervical ripening and abortifacient, convenient use, safety and reliability, is suitable for premature rupture of membranes at term labor.